OS among sorafenib patients (dashed line) and controls (solid line). Only controls alive and without disease relapse at the median date of sorafenib initiation (+68) were included. Patients given sorafenib maintenance had a significantly higher OS than controls at 2 years (P = .029). Adapted from Brunner et al³⁴  with permission.